View on market: Stay Cautious, be with quality business:
Most Asian stocks dipped Wednesday after robust U.S. economic data lifted Wall Street shares, Treasury yields and the dollar and prompted more calls for tighter monetary policy. Shares were lower in Japan, South Korea and Australia. U.S. futures were little changed after American benchmarks extended a rally, buoyed by expanding retail sales and factory output. A call for more hawkish monetary policy from Federal Reserve Bank of St. Louis President James Bullard underlined worries that high inflation could eventually bite. The Singapore-traded SGX Nifty, an early indicator of India’s Nifty 50 Index’s performance, fell 0.34% to 17,941.50, as of 8:05 a.m. Treasuries held losses, with the 10-year yield above 1.6%. Traders are waiting to see the strength of demand at an auction of 20-year notes Wednesday. The dollar was near the highest level in 12 months. Markets are waiting for President Joe Biden to select the Fed chair nominee.
Economic Calendar:
- INR: M3 Money Supply on 17th November, 2021.
- INR: Bank Loan & Deposit Growth on 19th November, 2021.
- USD: Building Permits (Oct) on 17th November, 2021.
- USD: Crude Oil Inventories on 17th November, 2021.
Brokerage Radar:
CLSA ON L&T: Maintain buy at the price of Rs 1950 for the target price of Rs 2250. Upbeat on infrastructure capex; guidance on track. Divestment on track but some delays possible. Confident on margins; ESG focus gets a leg up; look out for five-year plan.
CREDIT SUISSE ON ASHOK LEYLAND: Maintain neutral at the price of Rs 146.20 for the target price of Rs 135. High competitive intensity & full valuations keep them on sidelines. Trades at 14.9x FY23 core EV/EBITDA. Trim their FY22 and FY23 EPS by ~10% each.
International Markets:
U.S & Europe
| Particulars | 16th Nov | Chg | Chg(%) |
| Nasdaq | 15,973.86 | 120.01 | 0.76 |
| Dow | 36,142.22 | 54.77 | 0.15 |
| FTSE | 7,326.97 | -24.89 | -0.34 |
| CAC | 7,152.60 | 23.97 | 0.34 |
| DAX | 16,247.86 | 99.22 | 0.61 |
| Dow Fut.* | 36,085.00 | 24.00 | 0.07 |
Asian markets:
| Particulars | 17th Nov | Chg | Chg(%) |
| SGX Nifty | 17,941.50 | -63.50 | -0.35 |
| Nikkei | 29,679.34 | -128.78 | -0.43 |
| Straits Times | 3,227.68 | -11.12 | -0.34 |
| Hang Seng | 25,566.99 | -146.79 | -0.57 |
| Shanghai | 3,529.54 | 7.75 | 0.22 |
ADR Watch:
| Particulars | 16th Nov | Chg | Chg(%) |
| Dr Reddy | 64.11 | -1.27 | -1.94 |
| HDFC Bank | 70.39 | -0.59 | -0.83 |
| ICICI Bank | 20.31 | -0.21 | -1.02 |
| Infosys | 24.03 | 0.40 | 1.69 |
| Tata Motor | 34.66 | 1.09 | 3.25 |
| Wipro | 9.09 | 0.04 | 0.44 |
Commodities & Currency
| Particulars | Current Price | Chg(%) |
| USD/INR | 74.37 | -0.15 |
| Brent | 81.77 | -0.74 |
| Gold | 1856.35 | 0.12 |
| Silver | 25.017 | 0.29 |
FIIs & DII
| Particulars | 16th Nov | 15th Nov |
| FIIs | -560.67 | 424.74 |
| DIIs | 577.34 | 1524.67 |
News Update:
Biocon: Biocon Biologics and Viatris Inc. have launched interchangeable SEMGLEE (insulin glargineyfgn) injection and Insulin Glargine (insulin glargine-yfgn) injection in U.S. to help control high blood sugar in adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes.
InterGlobe Aviation: IndiGo has scrapped plans to raise funds as revenue recovers. IndiGo is unlikely to raise funds through a share sale to institutional investors, as the carrier’s revenue is recovering and there are no signs of third wave of the Covid pandemic erupting in India, CEO Ronojoy Dutta said. The budget carrier is also mulling charging passengers for checked-in luggage.
Infosys and MIT Technology Review launched ‘The Cloud Hub’, a forum offering insights and learning from successful cloud transformations to help global enterprises accelerate their cloud journey.
ITC: ITC Hotels’ luxury brand Mementos has signed a new property in Jaipur strengthening its presence in Rajasthan. Under this brand, ITC Hotels manages luxury properties. Last week the company has signed another hotel in Udaipur in Rajasthan. Both properties, the company added, will cater to the destination wedding segment.
Coforge Ltd: Shareholders of the company, earlier known as NIIT Technologies, including its controlling owner Baring Private Equity Asia, will sell securities worth as much as $750 million in a proposed American Depositary Receipts offering in the US. On Tuesday, Coforge filed an offer document informing the stock exchanges that its shareholders will sell ADRs in a US IPO.
Aviation stocks: The Ministry of Civil Aviation on Tuesday allowed resumption of meal services on all domestic flights, easing more of covid-induced curbs amid a steady decline in fresh daily cases. Since the onset of the pandemic, meal services were restricted only for flights whose duration lasts for more than two hours.
PVR: CEO Gautam Dutta said the multiplex chain operator is looking forward to having “the biggest quarter” in the January-March 2022 period of the ongoing fiscal as more states lift covid-19 related restrictions with a huge amount movie releases lined up in the coming months. The company is also bullish on audiences coming back to theatres with occupancy levels at theatres gradually inching towards pre-pandemic levels across the country.
Dr Reddy’s: Pfizer Inc and the Medicines Patent Pool, a UN-backed public health organisation have announced the signing of a voluntary license agreement for Pfizer’s Covid-19 oral antiviral treatment. Dr. Reddy’s Laboratories, among the handful of Indian drug companies licensed to make a new covid-19 pill developed by Merck, said on Monday it was open to making a similar pill from Pfizer, thought to be even more effective.
Source: Moneycontrol, Livemint,, Bloomberg, Investing
Disclosure in pursuance of Section 19 of SEBI (RA) Regulation 2014
Elite Wealth Limited does/does not do business with companies covered in its research reports. Investors should be aware that the Elite Wealth Limited may/may not have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only information in making their investment decision and must exercise their own judgment before making any investment decision.
For analyst certification and other important disclosures, see the Disclosure Appendix, or go to www.elitewealth.in. Analysts employed by Elite Wealth Limited are registered/qualified as research analysts with SEBI in India.( SEBI Registration No.: INH100002300)
Disclosure Appendix
Analyst Certification (For Reports)
Israil Khan, Elite Wealth Limited, suhail@elitewealth.in
The analyst(s) certify that all of the views expressed in this report accurately reflect my/our personal views about the subject company or companies and its or their securities. I/We also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Elite Wealth Limited.
As to each individual report referenced herein, the primary research analyst(s) named within the report individually certify, with respect to each security or issuer that the analyst covered in the report, that:
(1) all of the views expressed in the report accurately reflect his or her personal views about any and all of the subject securities or issuers; and
(2) no part of any of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in the report.
For individual analyst certifications, please refer to the disclosure section at the end of the attached individual notes.
Research Excerpts
This note may include excerpts from previously published research. For access to the full reports, including analyst certification and important disclosures, investment thesis, valuation methodology, and risks to rating and price targets, please visit www.elitewealth.in.
Company-Specific Disclosures
Important disclosures, including price charts, are available and all Elite Wealth Limited covered companies by visiting https://www.elitewealth.in, or emailing research@elitestock.com with your request. Elite Wealth Limited may screen companies based on Strategy, Technical, and Quantitative Research. For important disclosures for these companies, please e-mail research@elitestock.com.
Options related research:
If the information contained herein regards options related research, such information is available only to persons who have received the proper option risk disclosure documents. For a copy of the risk disclosure documents, please contact your Broker’s Representative or visit the OCC’s website at https://www.elitewealth.in
Other Disclosures
All research reports made available to clients are simultaneously available on our client websites. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research reports available on a particular stock, please contact your respective broker’s sales person.
Ownership and material conflicts of interest Disclosure
Elite Wealth Limited policy prohibits its analysts, professionals reporting to analysts from owning securities of any company in the analyst’s area of coverage. Analyst compensation: Analysts are salary based permanent employees of Elite Wealth Limited. Analyst as officer or director: Elite Wealth Limited policy prohibits its analysts, persons reporting to analysts from serving as an officer, director, board member or employee of any company in the analyst’s area of coverage.
Country Specific Disclosures
India – For private circulation only, not for sale.
Legal Entities Disclosures
Mr. Ravinder Parkash Seth is the Managing Director of Elite Wealth Ltd (EWL, henceforth), having its registered office at Casa Picasso, Golf Course Extension, Near Rajesh Pilot Chowk, Radha Swami, Sector-61, Gurgaon-122001 Haryana, is a SEBI registered Research Analyst and is regulated by Securities and Exchange Board of India. Telephone:011-43035555, Facsimile: 011-22795783 and Website: www.elitewealth.in
EWL discloses all material information about itself including its business activity, disciplinary history, the terms and conditions on which it offers research report, details of associates and such other information as is necessary to take an investment decision, including the following:
1. Reports
a) EWL or his associate or his relative has no financial interest in the subject company and the nature of such financial interest;
(b) EWL or its associates or relatives, have no actual/beneficial ownership of one per cent. or more in the securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;
(c) EWL or its associate or his relative, has no other material conflict of interest at the time of publication of the research report or at the time of public appearance;
2. Compensation
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) EWL or its associates have not managed or co-managed public offering of securities for the subject company in the past twelve months;
(c) EWL or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(d) EWL or its associates have not received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(e) EWL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report.
3 In respect of Public Appearances
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) The subject company is not now or never a client during twelve months preceding the date of distribution of the research report and the types of services provided by EWL